How will leadership and changes in Washington will affect the venture capital industry?

Mark Heesen, president of the National Venture Capital Association, will lead a private interactive session hosted by New Jersey Technology Council Capital Conference, Friday, Jan. 28. to shed light on aspects of the new Congress in terms of taxation, regulation of VCs, life sciences, immigration and research and development. The state of the venture industry in terms of investment, LP commitments and exits will also be examined. Fee is $50. Westin Princeton, Princeston, New Jersey.

Or choose to meet more than 30 VC funds and angel groups in one night at a Reverse Venture Fair, sponsored by Credit Suisse & Ameritech Media, Thursday, Feb. 3, in New York.

Investors include ARC Angel Fund, i-Hatch Ventures, Security Growth Partners, Trident Capital, Jumpstart NJ Angel Network, Launch Capital, ff Asset Management, NYC Seed, Tri-State Private Investors Network, Genacast Ventures, Osage Partners, Golden Seeds, GSA Venture Partners, Originate Ventures, Vital Financial, Connecticut Innovations, Long Island Angel Network, Angel Investor Forum, Firstmark Capital, Clove Hitch Partners, NY Angels, Kestrel Asset Management, Stonehenge Growth Capital, NYC Investment Fund, Centripetal Capital Partners, StarVest Partners, Innovation Ventures, Metamorphic Ventures, Liquidity Works, Vencon Management, Zelkova Ventures, Radius Ventures, Edison Venture Fund.

Related events worth a look:

BIO CEO & Investor Conference, Monday, Feb. 14, New York, is the largest investor conference focused on publicly-traded biotech companies. Details,

Venturefest Yorkshire, Wednesday, Feb. 16, is a one-day expo to connect the finest science, technology and knowledge entrepreneurs, the professional services who support them, and world-class business speakers. Note that this event is in the UK. Information,

Hear about best biotech business model practices at a MHT’s 2011 BioForum breakfast, Thursday, Feb. 17, 7:30 to 10 a.m., Merck Research Laboratories, Boston, Mass. Fee, $90. A portion of ticket proceeds will go to ocular melanoma research.